Specialty Pharmaceutical Company dedicated to patients living with chronic conditions

Filing date Description Form Filing Group Filer View

Report of unscheduled material events or corporate event

8-K
Current Reports
0001103021-19-000031.pdf 0001103021-19-000031.rtf 0001103021-19-000031.xls View HTML

Quarterly report which provides a continuing view of a company's financial position

10-Q
Quarterly Filings
0001103021-19-000033.pdf 0001103021-19-000033.rtf 0001103021-19-000033.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT View HTML

Statement of changes in beneficial ownership of securities

4
3,4,5
ODONNELL FRANCIS E JR 0001103021-19-000027.pdf 0001103021-19-000027.rtf View HTML

Statement of changes in beneficial ownership of securities

4
3,4,5
ODONNELL FRANCIS E JR 0001103021-19-000025.pdf 0001103021-19-000025.rtf View HTML

Statement of changes in beneficial ownership of securities

4
3,4,5
Sirgo Mark A 0001103021-19-000023.pdf 0001103021-19-000023.rtf View HTML

Statement of changes in beneficial ownership of securities

4
3,4,5
ODONNELL FRANCIS E JR 0001103021-19-000020.pdf 0001103021-19-000020.rtf View HTML

Statement of changes in beneficial ownership of securities

4
3,4,5
Sirgo Mark A 0001103021-19-000021.pdf 0001103021-19-000021.rtf View HTML

Statement of changes in beneficial ownership of securities

4
3,4,5
ODONNELL FRANCIS E JR 0001103021-19-000017.pdf 0001103021-19-000017.rtf View HTML

Statement of changes in beneficial ownership of securities

4
3,4,5
Sirgo Mark A 0001103021-19-000015.pdf 0001103021-19-000015.rtf View HTML

EFFECT

EFFECT
Other
9999999995-19-002089.pdf 9999999995-19-002089.rtf View HTML

Copyright Morningstar

BioDelivery Sciences Acquires U.S. Commercial Rights to Symproic®
Thank you. We will get back to you soon